Emerging SARS-CoV-2 variants, particularly the Omicron variant and its sublineages, continually threaten the global public health. Small molecule antivirals are an effective treatment strategy to fight against the virus. However, the first-generation antivirals either show limited clinical efficacy and/or have some defects in pharmacokinetic (PK) properties. Moreover, with increased use of these drugs across the globe, they face great pressure of drug resistance. We herein present the discovery and characterization of a new generation antiviral drug candidate (SY110), which is a potent and selective inhibitor of SARS-CoV-2 main protease (Mpro). This compound displayed potent in vitro antiviral activity against not only the predominant SARS-CoV-2 Omicron sublineage BA.5, but also other highly pathogenic human coronaviruses including SARS-CoV-1 and MERS-CoV. In the Omicron-infected K18-hACE2 mouse model, oral treatment with SY110 significantly lowered the viral burdens in lung and alleviated the virus-induced pathology. Importantly, SY110 possesses favorable PK properties with high oral drug exposure and oral bioavailability, and also an outstanding safety profile. Furthermore, SY110 exhibited sensitivity to several drug-resistance Mpro mutations. Collectively, this investigation provides a promising new drug candidate against Omicron and other variants of SARS-CoV-2.
Tropomyosin receptor kinases (TrkA,
TrkB, and TrkC) are attractive
therapeutic targets for multiple cancers. Two first-generation small-molecule
Trks inhibitors, larotrectinib and entrectinib, have just been approved
to use clinically. However, the drug-resistance mutations of Trks
have already emerged, which calls for new-generation Trks inhibitors.
Herein, we report the structural optimization and structure–activity
relationship studies of 6,6-dimethyl-4-(phenylamino)-6H-pyrimido[5,4-b][1,4]oxazin-7(8H)-one derivatives as a new class of pan-Trk inhibitors. The prioritized
compound 11g exhibited low nanomolar IC50 values
against TrkA, TrkB, and TrkC and various drug-resistant mutants. It
also showed good kinase selectivity. 11g displayed excellent in vitro antitumor activity and strongly suppressed Trk-mediated
signaling pathways in intact cells. In in vivo studies,
compound 11g exhibited good antitumor activity in BaF3-TEL-TrkA
and BaF3-TEL-TrkCG623R allograft mouse models without exhibiting
apparent toxicity. Collectively, 11g could be a promising
lead compound for drug discovery targeting Trks and deserves further
investigation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.